Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578-02 first-line combination therapy in unresectable colorectal cancer
jRCT2031200215Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 in colorectal cancer (CRC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Jan 2021; status: active, not recruiting.
02
Drugs
ONO-4578
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031200215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200215.